Assessment of Efficacy and Safety Issues of Current Biological Agents in Management of Asthma

ABSTRACT Around 5%–10% of people with asthma have severe or uncontrolled type of asthma, which is linked to higher hospitalization, higher death rates, higher health care costs, and lower quality of life. Recent years have seen the introduction of novel medications and the identification of multiple asthma phenotypes based on specific biomarkers. The management and treatment of severe asthma have been completely transformed by biologic therapy, which has demonstrated excellent therapeutic efficacy and substantial clinical advantages. In addition to enhancing the quality of life for individuals with severe asthma, biologic therapy significantly reduces exacerbations, hospital visits, and the requirement for continuous systemic steroids. Their therapeutic efficacy is demonstrated by randomized controlled trials (RCTs), extended research, metaanalyses, and real‐world data. The development and registration of biologics, new systemic medications for severe asthma are the main topics of this study, which also describes possible future treatment strategies. PubMed, Scopus, and Google Scholar were used to examine the content of recent medical literature. The results of early, important RCTs and later research into biologics for severe types of asthma are summarized in this study. Their safety and effectiveness results, which were obtained in a range of contexts, improved their generalizability and offer useful insights into their use.